Ifosfamide shortage puts cancer treatment at risk

Ifosfamide supplies at risk across Europe

Some people with lung cancer across Europe are facing a serious challenge after confirmation of an ongoing shortage of ifosfamide, a chemotherapy medicine used to treat lung cancer and other cancers.

The European Medicines Agency confirmed the shortage on 13 February 2026. Supplies are expected to remain severely limited until at least the first quarter of 2027.

The shortage affects all EU and EEA member states. It is linked to a technical problem at a manufacturing site operated by Baxter, along with site improvements required after a regulatory inspection in September 2025. The issue is not related to the quality or safety of the medicine itself.

Ifosfamide, sold under brand names including Holoxan, Tronoxal and Mitoxana, is used in combination chemotherapy regimens for lung cancer and several other cancers, including sarcomas, lymphomas, testicular cancer and ovarian cancer. Limited availability may lead to treatment delays or the need to use alternative therapies.

The EMA Executive Steering Group on Shortages is monitoring the situation and working with manufacturers and national regulators to reduce disruption. Healthcare professionals are advised to check supply before starting treatment.

Lung Cancer Europe encourages anyone who is concerned about their treatment to speak directly with their oncology team. Further updates are available from national medicines authorities and the European Medicines Agency.